Total submissions: 24
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000212363 | SCV000167593 | benign | not specified | 2014-01-13 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV000124179 | SCV000212843 | benign | Hereditary cancer-predisposing syndrome | 2019-10-07 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001083285 | SCV000252790 | benign | Hereditary diffuse gastric adenocarcinoma | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000488346 | SCV000575056 | likely benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | CDH1: BP4, BP7, BS1 |
Color Diagnostics, |
RCV000124179 | SCV000684348 | likely benign | Hereditary cancer-predisposing syndrome | 2015-10-19 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000488346 | SCV000698357 | benign | not provided | 2016-06-20 | criteria provided, single submitter | clinical testing | Variant summary: The CDH1 c.1272C>T (p.Val424Val) variant causes a synonymous change involving a non-conserved nucleotide with 5/5 splice prediction tools predicting no significant effect on splicing, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 94/121412 (1/1292), which significantly exceeds the estimated maximal expected allele frequency for a pathogenic CDH1 variant of 1/35336 (0.0000283), suggesting this variant is likely a benign polymorphism. Mulitple reputable clinical laboratories cite the variant as "likely benign/benign." Therefore, taking all available lines of evidence into consideration and based on the high allele frequency in the general population, the variant of interest has been classified as Benign. |
ARUP Laboratories, |
RCV000488346 | SCV000883549 | benign | not provided | 2022-11-28 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000212363 | SCV000889245 | benign | not specified | 2021-05-17 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000488346 | SCV002009864 | likely benign | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV001798417 | SCV002043249 | likely benign | Breast and/or ovarian cancer | 2023-03-09 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000212363 | SCV002064828 | likely benign | not specified | 2022-01-04 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000124179 | SCV002531154 | benign | Hereditary cancer-predisposing syndrome | 2021-01-09 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000212363 | SCV002551770 | likely benign | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
European Reference Network on Genetic Tumour Risk Syndromes |
RCV001083285 | SCV003926764 | likely benign | Hereditary diffuse gastric adenocarcinoma | 2022-08-01 | criteria provided, single submitter | clinical testing | BS1; BS2_Supporting (PMID: 30311375) |
Breakthrough Genomics, |
RCV000488346 | SCV005219061 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Myriad Genetics, |
RCV001083285 | SCV005404146 | benign | Hereditary diffuse gastric adenocarcinoma | 2024-09-18 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |
Mayo Clinic Laboratories, |
RCV000212363 | SCV000691819 | likely benign | not specified | no assertion criteria provided | clinical testing | ||
True Health Diagnostics | RCV000124179 | SCV000787974 | likely benign | Hereditary cancer-predisposing syndrome | 2017-10-11 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003891656 | SCV000806634 | benign | CDH1-related disorder | 2020-08-08 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Diagnostic Laboratory, |
RCV000488346 | SCV001742115 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000212363 | SCV001809278 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000212363 | SCV001923364 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000212363 | SCV001953596 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000212363 | SCV001968963 | benign | not specified | no assertion criteria provided | clinical testing |